CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
GORE TAG® Thoracic Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00608829
NCT00608829Phase 2Completed
CompareCT.gov

Evaluation of the GORE TAG® Thoracic Endoprosthesis - 45 mm for the Primary Treatment of Aneurysms of the Descending Thoracic Aorta

W.L.Gore & Associates·interventional·Posted Feb 6, 2008·Updated Mar 5, 2015

In Brief

A Phase 2 clinical trial evaluating GORE TAG® Thoracic Endoprosthesis for Aortic Aneurysm, Thoracic. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The objective of this study is to assess the safety and efficacy of the 45 mm TAG device in subjects with aneurysms of the descending thoracic aorta.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Aneurysm, Thoracic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2008
Enrollment StartFeb 1, 2007
Primary CompletionAug 1, 2009
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.4 years ago

Interventions

GORE TAG® Thoracic Endoprosthesisdevice

Implant